Abstract
Iloperidone is a second-generation antipsychotic that was approved on May 6, 2009 by the FDA for treating schizophrenia in adults. It is a piperidinyl-benzisoxasole derivative with mixed dopamine (D2) and serotonin (5-HT2A) antagonist properties. Interestingly, as specified in the product labelling, numerous cases of dose-dependent QT interval prolongation have been reported with iloperidone. Our aims were therefore to evaluate the effects of iloperidone on cardiac ventricular repolarization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
